Apellis Pharmaceuticals Inc (APLS.OQ)
APLS.OQ on NASDAQ Stock Exchange Global Select Market
18.88USD
18 Apr 2019
18.88USD
18 Apr 2019
Change (% chg)
$0.23 (+1.23%)
$0.23 (+1.23%)
Prev Close
$18.65
$18.65
Open
$18.66
$18.66
Day's High
$18.92
$18.92
Day's Low
$18.37
$18.37
Volume
72,626
72,626
Avg. Vol
113,307
113,307
52-wk High
$26.56
$26.56
52-wk Low
$11.45
$11.45
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Dec '18 | 0.00 | -0.648 |
| Sep '18 | 0.00 | -0.640 | |
| Jun '18 | 0.00 | -0.609 | |
| Mar '18 | 0.00 | -0.432 | |
| FY 2017 | Dec '17 | 0.00 | -0.371 |
| Sep '17 | 0.00 | -0.235 | |
| Jun '17 | 0.00 | -0.246 | |
| Mar '17 | 0.00 | -0.184 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-19 | 3 | 0.00 | 0.00 | 0.00 | -- |
| Quarter Ending Sep-19 | 3 | 0.00 | 0.00 | 0.00 | -- |
| Year Ending Dec-19 | 4 | 0.00 | 0.00 | 0.00 | 0.00 |
| Year Ending Dec-20 | 3 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earnings (per share) | |||||
| Quarter Ending Jun-19 | 5 | -0.67 | -0.58 | -0.76 | -- |
| Quarter Ending Sep-19 | 5 | -0.70 | -0.60 | -0.81 | -- |
| Year Ending Dec-19 | 5 | -2.77 | -2.51 | -3.06 | -1.54 |
| Year Ending Dec-20 | 4 | -3.17 | -2.82 | -3.32 | -1.89 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 58.59 | 59.19 | |
| P/E High - Last 5 Yrs. | -- | 49.29 | 56.13 | |
| P/E Low - Last 5 Yrs. | -- | 27.60 | 28.61 | |
| Beta | -- | 0.93 | 0.93 | |
| Price to Sales (TTM) | -- | 7.25 | 9.24 | |
| Price to Book (MRQ) | 6.52 | 3.96 | 4.50 | |
| Price to Tangible Book (MRQ) | 7.22 | 6.80 | 7.49 | |
| Price to Cash Flow (TTM) | -- | 41.19 | 41.02 | |
| % Owned Institutions | -- | 0.00 | 0.00 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.67 | 1.52 | |
| Dividend Yield - 5 Year Avg | -- | 0.72 | 0.71 | |
| Dividend 5 Year Growth Rate | -- | 2.12 | 3.02 | |
| Payout Ratio(TTM) | -- | 21.94 | 22.19 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -- | 7.65 | 9.20 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -- | 4.62 | 8.53 | |
| Sales - 5 Yr. Growth Rate | -- | 9.74 | 11.00 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -74.81 | 136.77 | 110.06 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -124.92 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 5.20 | 6.93 | |
| Capital Spending - 5 Yr. Growth Rate | -- | 6.53 | 7.54 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 2.67 | 2.67 |
| Current Ratio (MRQ) | 11.89 | 3.69 | 3.63 |
| LT Debt to Equity (MRQ) | 15.77 | 12.67 | 13.50 |
| Total Debt to Equity (MRQ) | 16.80 | 15.36 | 17.19 |
| Interest Coverage (TTM) | -202.57 | 30.89 | 27.63 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 51.89 | 50.52 | |
| Gross Margin - 5 Yr. Avg. | -- | 50.00 | 50.88 | |
| EBITD Margin (TTM) | -- | -- | -- | |
| EBITD - 5 Yr. Avg | -- | 17.22 | 15.81 | |
| Operating Margin (TTM) | -- | 9.60 | 3.26 | |
| Operating Margin - 5 Yr. Avg. | -- | 13.49 | 11.13 | |
| Pre-Tax Margin (TTM) | -- | 8.83 | 2.52 | |
| Pre-Tax Margin - 5 Yr. Avg. | -- | 20.22 | 16.73 | |
| Net Profit Margin (TTM) | -- | 5.06 | -1.40 | |
| Net Profit Margin - 5 Yr. Avg. | -- | 15.10 | 11.71 | |
| Effective Tax Rate (TTM) | -- | 22.69 | 22.81 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 23.67 | 23.92 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 0 | 897,836,113 | 767,992,236 | |
| Net Income/Employee (TTM) | -1,465,542 | 103,382,567 | 88,430,036 | |
| Receivable Turnover (TTM) | -- | 5.41 | 5.22 | |
| Inventory Turnover (TTM) | -- | 2.62 | 3.67 | |
| Asset Turnover (TTM) | 0.00 | 0.84 | 0.80 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -66.12 | 9.92 | 9.53 | |
| Return on Assets - 5 Yr. Avg. | -71.76 | 10.99 | 10.46 | |
| Return on Investment (TTM) | -70.43 | 12.14 | 11.77 | |
| Return on Investment - 5 Yr. Avg. | -76.64 | 14.01 | 13.34 | |
| Return on Equity (TTM) | -82.28 | 13.10 | 12.61 | |
| Return on Equity - 5 Yr. Avg. | -291.97 | 15.25 | 14.81 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -- | -- | -- |
| EPS (TTM) % | -126.36 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Apellis Pharmaceuticals Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | -2.25 | -4.82 | 97 | 9 |
| 13 Week | 23.67 | 11.55 | 99 | 8 |
| 26 Week | 11.61 | 8.10 | 99 | 42 |
| 52 Week | -25.46 | -30.45 | 75 | 46 |
| YTD | 41.40 | 22.21 | 99 | 18 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
Institutional Holders
| % Shares Owned: | 53.65% |
| # of Holders: | 140 |
| Total Shares Held: | 33,415,473 |
| 3 Mo. Net Change: | 17,851 |
| # New Positions: | 1 |
| # Closed Positions: | 2 |
| # Increased Positions: | 5 |
| # Reduced Positions: | 11 |
| # Net Buyers: | -6 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.